Physician profile
Verna Porter
NPI 1730107012
$4,886.84
in general payments reported to CMS, 2019-2025
29 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $1,278 · 2021: $137 · 2022: $187 · 2023: $635 · 2024: $651 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,423.86 | 2020-2025 | Leqembi |
| Ucb, INC. | $824.59 | 2023-2025 | Zilbrysq, Rystiggo |
| Csl Behring | $475.71 | 2019-2025 | Hizentra |
| Acadia Pharmaceuticals INC | $433.00 | 2019-2025 | Nuplazid |
| Lilly USA, LLC | $274.35 | 2022-2024 | Amyvid, Kisunla |
| Argenx US, INC. | $264.01 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Takeda Pharmaceuticals U.S.A., INC. | $187.80 | 2022-2025 | Hyqvia, Gammagard |
| Merz Pharmaceuticals, LLC | $130.44 | 2021-2025 | Inbrija, Xeomin |
| Lundbeck LLC | $114.07 | 2020-2023 | Rexulti |
| Alexion Pharmaceuticals, INC. | $99.23 | 2021-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $76.19 | 2023-2024 | Ingrezza, Ongentys |
| Catalyst Pharmaceuticals, INC. | $63.01 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $58.40 | 2021-2025 | Crexont |
| Ipsen Biopharmaceuticals, INC | $52.64 | 2025 | Dysport |
| Eisai INC. | $47.40 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $39.52 | 2025 | |
| Ge Healthcare | $39.27 | 2022-2025 | |
| Medtronic, INC. | $36.67 | 2021 | |
| Akcea Therapeutics, INC. | $32.68 | 2020 | |
| Abbvie INC. | $27.70 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $27.26 | 2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $24.91 | 2019 | |
| Abbott Laboratories | $23.06 | 2025 | Infinity |
| Idorsia Pharmaceuticals US INC | $21.55 | 2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $19.79 | 2025 | Wainua |
| Novartis Pharmaceuticals Corporation | $19.26 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.81 | 2020 | |
| Xeris Pharmaceuticals, INC. | $16.68 | 2021 | |
| Acorda Therapeutics, INC | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verna Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.